Sun Pharmaceutical Industries Ltd, which has been embroiled in a patent lawsuit in the US since last year over its specialty drug Leqselvi, received a favourable ruling from a court, paving the ...

Indian benchmark Nifty 50 spent the day in the green. Nifty opened at 24,070 and ended the day at 24,329 gaining 289 points.

After falling 17 per cent since the start of the year to its March lows, the stock of the country's largest pharmaceutical ...

Sun Pharma had appealed against the District of New Jersey’s decision that had previously granted a preliminary injunction delaying its launch of Leqselvi (deuruxolitinib) in the United States.

US Court vacates injunction, allowing Sun Pharma to launch Leqselvi Emkay Global suggests a royalty-based settlement with Incyte Leqselvi's US sales projected at $40 million in FY26, $124 million ...

While others played safe, Shanghvi bet on complex generics and specialty pharma, and rode a wave of acquisitions to make Sun ...

After a legal decision delayed its entry last fall, Sun Pharma has received the all-clear to tap into the U.S. alopecia market with its JAK inhibitor Leqselvi, teeing up a potential showdown with ...

The upside is due to a positive ruling by the US court regarding the launch of Leqselvi. The US Court heard arguments in the pharmaceutical company’s appeal against a previous decision by the ...

“The company is no longer under a court order that delays or restricts the Company from launching Leqselvi. The Company will disclose the launch plans in due course of time,” it adde ...

Sun Pharma has been locked in a patent infringement litigation with Incyte Corporation over LEQSELVI (deuruxolitinib). On April 9, 2025, the US Court of Appeals for the Federal Circuit held an ...

Sun Pharmaceutical Industries stock ended 2.15 per cent higher on Friday after zooming by almost 5 per cent in the morning trade on the back of an announcement that a court ruling has cleared the deck ...